Occurrence of multidrug resistant and extended spectrum β-lactamase (ESBL) - producing Escherichia coli in wastewater of two healthcare facilities in Ibadan, Nigeria

• Autorzy: Adekanmbi A.O. , Adeyemi A.O. , Olajide O.M.
• Języki publikacji: EN

Abstrakty

EN

Most industries in developing countries of the world, especially hospitals and other clinical settings, lack wastewater treatment facilities, and as such, untreated wastewater from their operations are discharged into water bodies without any form of treatment. This study aimed at the antibiotic sensitivity profile and ESBL production in E. coli isolated from untreated hospital wastewater before discharge into the environment. Untreated wastewater from two hospitals, a State Government-owned hospital (SGH) and a privately-owned hospital (POH) with no wastewater treatment facilities were sampled for a period of four months. Isolation of E. coli was carried out using the pour plate technique on Eosin Methylene Blue agar, while identification was carried out using conventional methods. Determination of ESBL production was done by means of the Double Disc Synergy Technique and antibiotic sensitivity testing was carried out by employing the disc diffusion method. A total of fiftyeight (58) E. coli were obtained: SGH at 55 and POH at 3. Herein, in 100% of the total count, resistance was indicated for ampicillin and ertapenem, while 14%, 11%, 16% and 57% of the total count were resistant to ceftazidime, cefpodoxime, cefotaxime and amoxicillin-clavulanate, respectively. In addition, 94.8% showed resistance to tetracycline, 19% to ciprofloxacin, 6.9% to gentamycin, 39.7% to chloramphenicol and 55% and 47% to sulfamethoxazole-trimethoprim and nalidixic acid, respectively. Furthermore, 94.8% of all the isolates were multidrug resistant (MDR), while 29.3% were ESBL positive. Wastewater from the two hospitals under study contained ESBL positive and MDR E. coli, suggesting a need to forestall a potential threat to public health by treating the wastewater generated by both hospitals before discharge into the environment.

• Wydawca: -
• Czasopismo: World News of Natural Sciences
• Rocznik: 2019
• Tom: 26
• Opis fizyczny: p.167-175,fig.,ref.

Twórcy

autor

Adekanmbi A.O.

• Environmental Microbiology and Biotechnology Laboratory, Department of Microbiology, University of Ibadan, Ibadan, Nigeria

autor

Adeyemi A.O.

• Environmental Microbiology and Biotechnology Laboratory, Department of Microbiology, University of Ibadan, Ibadan, Nigeria

autor

Olajide O.M.

• Environmental Microbiology and Biotechnology Laboratory, Department of Microbiology, University of Ibadan, Ibadan, Nigeria

Bibliografia

• [1] Andy IE, Okpo EA. Prevalence of potential nosocomial bacterial pathogens in liquid waste and waste dump soil of three major hospitals in Calabar Metropolis, South, Nigeria. World Journal of Pharmaceutical Research (2018), 7(17): 134-147.
• [2] Andy IE, Okpo, EA. (2018). Occurrence and Antibiogram of Bacteria Isolated from Effluent and Waste Dump Site Soil of Selected Hospitals in Calabar Metropolis, Nigeria. Microbiology Research Journal International, 25(5): 1-9.
• [3] Berkner S, Konradi S, Schönfeld J. Antibiotic resistance and the environment — there and back again. Unit IV .2 Pharmaceuticals, Washing and Cleansing Agents and Nanomaterials, Federal Environment Agency, Dessau, Germany. 2014.
• [4] Blaak H, Lynch G, Italiaander R, Hamidjaja RA, Schets FM, de Roda Husman AM. Multidrug-resistant and extended spectrum beta-lactamase-producing Escherichia coli in Dutch surface water and wastewater. PLoS ONE. 2015; 10:1-16 e0127752.
• [5] Bréchet C, Plantin j, Sauget M, Thouverez M, Talon D, Cholley P, Guyeux C, Hocquet D, Bertrand X. Wastewater Treatment Plants Release Large Amounts of Extended-Spectrum -Lactamase-Producing Escherichia coli into the Environment. Clinical Infectious Diseases 2014; 58(12): 1658-1665.
• [6] Canto´n RA, Oliver TM, Coque M, del Carmen Varela JC, Pe´rez-Dı´az A, F Baquero F. 2002. Epidemiology of extended-spectrum beta-lactamase producing Enterobacter isolates in a Spanish hospital during a 12-year period. Clin. Microbiol. 2002; 40: 1237-1243.
• [7] Chitnis V, Chitnis S, Vaidya K, Ravikant S, Patil S, Chitnis DS. Bacterial population changes in hospital effluent treatment plant in central India. Water Res. 2004: 38: 441-447.
• [8] Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 27th ed. CLSI supplement M100. Wayne, PA: 2018.
• [9] Elmanama AA, ElKichaoui AY Mohsin M. Contribution of Hospital Wastewater to the Spread of Antibiotic Resistance in Comparison to Non-Health Institution. J. Al-Aqsa Unv. 2006; 10:108-121.
• [10] Falodun OI, Oladimeji OS. Extended Spectrum Beta Lactamase (ESBL) producing enteric bacteria from hospital wastewater, Ibadan, Nigeria. World News of Natural Sciences 2019. 22: 62-74
• [11] Gaskin HR, Collier CT, Anderson DB. Antibiotics as growth promotants: mode of action. Anim. Biotechnol. 2002; 13: 29-42.
• [12] Goni-Urriza, M., Capdepuy, M., Arpin, C., Raymond, N., Caumette, P., Quentin, C. Impact of an urban effluent on antibiotic resistance of riverine Enterobacteriaceae and Aeromonas spp. Appl. Environ. Microbiol. 2000; 66: 125-132.
• [13] Harrigan WF, McCance MF. Laboratory methods in Food and Dairy Microbiology (Revised Edition). 452 S., 24 Abb. London-New York-San Francisco. Z Allg Mikrobiol. 1976; 18: 226-227.
• [14] Katouli M, Thompson J, Gündoğdu A, Stratton HM. Antibiotic resistant bacteria in hospital wastewaters and sewage treatment plants. Sci. Forum Stakeholder Engage. 2012; 13: 225-229.
• [15] Kim S, Aga DS. Potential ecological and human impacts of antibiotics and antibiotic-resistant bacteria from wastewater treatment plants. Toxicol. Environ. Health B Crit. Rev. 2007; 10: 559-573.
• [16] Kolar M, Urbanek K, Latal T. 2001. Antibiotic selective pressure and development of bacterial resistance. Int. J. Antimicrob. Agents. 2001; 7:357-366.
• [17] Kummerer K. Antibiotics in the aquatic environment - a review - Part 1. Chemosphere. J Chemosphere (2009), 75: 417-434.
• [18] Lateef, A. The microbiology of a pharmaceutical effluent and its public health implications. World Journal of Microbiology and Biotechnology 2004; 20: 167-171.
• [19] Lien L.T., Hoa N.Q., Chuc N.T., Thoa N.T., Phuc H.D., Diwan V., Dat N.T., Tamhankar A.J., Lundborg C.S. Antibiotics in Wastewater of a Rural and an Urban Hospital before and after Wastewater Treatment, and the Relationship with Antibiotic Use-A One Year Study from Vietnam. Int. J. Environ. Res. Public Health 2016; 13: 558-600.
• [20] Moges F., Endris M., Mulu A., Tessema B., Belyhun Y., Shiferaw Y., Huruy K., Unakal C., Kassu A. The growing challenges of antibacterial drug resistance in Ethiopia. J Glob. Antimicrob Resist. 2014; 2(3): 148-154.
• [21] Molstad S, Lundborg CS, Karlsson AK, Cars O. Antibiotic prescription rates vary markedly between 13 European countries. Scand. J. Infect. Dis Suppl. 2002; 34: 366-671.
• [22] Oberoi L, Singh N, Sharma P, Aggarwal A. ESBL, MBL and Ampc β Lactamases-producing Superbugs - Havoc in the Intensive Care Units of Punjab India. J Clin Diagn Res. 2013; 7: 70-73
• [23] Paterson DL and Bonomo RA. 2005. Extended-Spectrum β-Lactamases: a Clinical Update. Clin Microbiol Rev. 2005; 18: 657-686.
• [24] Sharmin S, Alamgir F, Fahmida M, Saleh A.A. Antimicrobial sensitivity pattern of uropathogens in children. Bangladesh Journal of Medical Microbiology. 2009; 3(2): 18-22.
• [25] Sharpe M. High on pollution: drugs as environmental contaminants. J Environ Monit. 2003; 5: 42–46.
• [26] Sneath PHA. Bergey’s manual of determinative bacteriology. William and Wilkins, Baltimore. 1996.